MedTrace Logo

Growth Hormone Signaling in Vivo in Humans

NCT00512473 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2007-08-07

No results posted yet for this study

Summary

Objective: GH induces insulin resistance in muscle and fat and in vitro data indicate that this may involve crosstalk between the signaling pathways of the two hormones.

Aim: To investigate GH and insulin signaling in vivo in human muscle and fat tissue in response to GH, GH receptor blockade and insulin stimulation..

Conditions

  • Intracellular Signaling Peptides and Proteins

Interventions

DRUG

Saline infusion

0.9 % NaCl

DRUG

Human Growth Hormone

0.5 mg genotropin administered as a bolus at t = 0

DRUG

Pegvisomant

30 mg Somavert administered at t = - 36 hours

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars C Gormsen, MD · Aarhus University Hospital, Department M

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Completion
2006-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512473 on ClinicalTrials.gov